Canada - English - Health Canada

sandoz canada incorporated - sodium phosphate monobasic; sodium phosphate dibasic - solution - 276mg; 268mg - sodium phosphate monobasic 276mg; sodium phosphate dibasic 268mg - replacement preparations

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratoires mayoly spindler - sodium phosphate monobasic; sodium phosphate dibasic, anhydrous - tablet - 1500 milligram(s) - osmotically acting laxatives; sodium phosphate

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals,inc. - sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (sodium cation - unii:lyr4m0nh37), sodium phosphate, dibasic, anhydrous (unii: 22ado53m6f) (sodium cation - unii:lyr4m0nh37) - monobasic sodium phosphate and dibasic sodium phosphate tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults. monobasic sodium phosphate and dibasic sodium phosphate tablets are contraindicated in the following conditions: -   history of acute phosphate nephropathy [see warnings and precautions (5.1)] -   gastrointestinal (gi) obstruction [see warnings and precautions (5.7)] -   gastric bypass or stapling surgery -   bowel perforation -   toxic colitis -   toxic megacolon -   hypersensitivity to sodium phosphate salts or any component of monobasic sodium phosphate and dibasic sodium phosphate tablets[see warnings and precautions (5.7)]. risk summary there are no available data on sodium phosphate use in pregnant women to inform a drug-associated risk for adverse developmental outcomes. animal reproduction studies have not been conducted with sodium phosphate. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. risk summary there are no data available to assess the presence of sodium phosphate in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. the lack of clinical data during lactation precludes a clear determination of the risk of monobasic sodium phosphate and dibasic sodium phosphate tablets to a child during lactation; therefore, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for monobasic sodium phosphate and dibasic sodium phosphate tablets and any potential adverse effects on the breastfed child from monobasic sodium phosphate and dibasic sodium phosphate tablets or from the underlying maternal condition. safety and effectiveness in pediatric patients have not been established. of the 599 patients in clinical trials receiving at least 48 grams of monobasic sodium phosphate and dibasic sodium phosphate tablets, 134 (22%) were 65 years of age or older, while 27 (5%) were 75 years of age or older. no overall differences in safety or effectiveness were observed between geriatric patients and younger patients. however, the mean phosphate levels in geriatric patients were greater than the phosphate levels in younger patients after monobasic sodium phosphate and dibasic sodium phosphate tablets administration. the mean colonoscopy-day phosphate levels in patients 18-64, 65-74, and ≥ 75 years old who received the recommended monobasic sodium phosphate and dibasic sodium phosphate tablets dosage regimen in study 1were 7.0, 7.3, and 8.0 mg/dl, respectively. after monobasic sodium phosphate and dibasic sodium phosphate tablets administration, the mean phosphate levels in patients 18-64, 65-74, and ≥ 75 years old were 7.4, 7.9, and 8.0 mg/dl, respectively. greater sensitivity of some older individuals cannot be ruled out; therefore, use monobasic sodium phosphate and dibasic sodium phosphate tablets with caution in geriatric patients. advise geriatric patients to adequately hydrate before, during, and after the use of monobasic sodium phosphate and dibasic sodium phosphate tablets. sodium phosphate is known to be substantially excreted by the kidney, and the risk of adverse reactions with sodium phosphate may be greater in patients with impaired renal function. since geriatric patients are more likely to have impaired renal function, consider performing baseline and post-colonoscopy labs (phosphate, calcium, potassium, sodium, creatinine, and bun) in these patients [see warnings and precautions (5.1)]. sodium phosphate is substantially excreted by the kidney. use monobasic sodium phosphate and dibasic sodium phosphate tablets with caution in patients with severe renal impairment (creatinine clearance less than 30 ml/min) or patients taking concomitant medications that may affect renal function. these patients may be at risk for renal injury. advise these patients of the importance of adequate hydration before, during and after the use of monobasic sodium phosphate and dibasic sodium phosphate tablets, and consider performing baseline and post-colonoscopy labs (phosphate, calcium, potassium, sodium, creatinine, and bun) in these patients [see warnings and precautions (5.1), drug interactions (7.1)] .

United States - English - NLM (National Library of Medicine)

c.b. fleet company, inc. - sodium phosphate, dibasic, heptahydrate (unii: 70wt22sf4b) (phosphate ion - unii:nk08v8k8hr, sodium cation - unii:lyr4m0nh37), sodium phosphate, monobasic (unii: 3980jih2sw) (sodium cation - unii:lyr4m0nh37, phosphate ion - unii:nk08v8k8hr) - sodium phosphate, dibasic, heptahydrate 3.5 g in 66 ml - saline laxative saline laxative for relief of occasional constipation.

United States - English - NLM (National Library of Medicine)

cdma - sodium phosphate, dibasic, unspecified form (unii: gr686lba74) (phosphate ion - unii:nk08v8k8hr, sodium cation - unii:lyr4m0nh37), sodium phosphate, monobasic, unspecified form (unii: 3980jih2sw) (phosphate ion - unii:nk08v8k8hr, sodium cation - unii:lyr4m0nh37) - sodium phosphate, dibasic 7 g in 118 ml - - relieves occasional constipation - this product generally produces bowel movement in 1 to 5 minutes

United States - English - NLM (National Library of Medicine)

gadal laboratories inc - sodium phosphate, dibasic (unii: gr686lba74) (phosphate ion - unii:nk08v8k8hr), sodium phosphate, monobasic (unii: 3980jih2sw) (phosphate ion - unii:nk08v8k8hr) - - rectal bleeding - no bowel movement within 30 minutes of enema use - symptoms of dehydration (feeling thirsty, dizziness, vomiting, urinating less often than normal) - each 59 ml delivered dose contains: sodium 2.2 g - additional liquids by mouth are recommended while taking this product - this product generally produces bowel movement in 1 to 5 minutes

United States - English - NLM (National Library of Medicine)

strategic sourcing services llc - sodium phosphate, dibasic, unspecified form (unii: gr686lba74) (phosphate ion - unii:nk08v8k8hr, sodium cation - unii:lyr4m0nh37), sodium phosphate, monobasic, unspecified form (unii: 3980jih2sw) (phosphate ion - unii:nk08v8k8hr, sodium cation - unii:lyr4m0nh37) - sodium phosphate, dibasic 7 g in 118 ml - - relieves occasional constipation - this product generally produces bowel movement in 1 to 5 minutes

United States - English - NLM (National Library of Medicine)

cardinal health - sodium phosphate, dibasic, unspecified form (unii: gr686lba74) (sodium cation - unii:lyr4m0nh37, phosphate ion - unii:nk08v8k8hr), sodium phosphate, monobasic, unspecified form (unii: 3980jih2sw) (sodium cation - unii:lyr4m0nh37, phosphate ion - unii:nk08v8k8hr) - sodium phosphate, dibasic 7 g in 118 ml - - relieves occasional constipation - this product generally produces bowel movement in 1 to 5 minutes

United States - English - NLM (National Library of Medicine)

c.b. fleet company, inc. - sodium phosphate, dibasic, heptahydrate (unii: 70wt22sf4b) (phosphate ion - unii:nk08v8k8hr, sodium cation - unii:lyr4m0nh37), sodium phosphate, monobasic (unii: 3980jih2sw) (phosphate ion - unii:nk08v8k8hr, sodium cation - unii:lyr4m0nh37) - sodium phosphate, dibasic, heptahydrate 7 g in 133 ml - for relief of occasional constipation or bowel cleansing before rectal examinations.

United States - English - NLM (National Library of Medicine)

c.b. fleet company, inc. - sodium phosphate, dibasic, heptahydrate (unii: 70wt22sf4b) (phosphate ion - unii:nk08v8k8hr, sodium cation - unii:lyr4m0nh37), sodium phosphate, monobasic (unii: 3980jih2sw) (phosphate ion - unii:nk08v8k8hr, sodium cation - unii:lyr4m0nh37) - sodium phosphate, dibasic, heptahydrate 3.5 g in 66 ml - for relief of occasional constipation or bowel cleansing before rectal examinations. - rectal bleeding - no bowel movement ater the enema is given these symptoms may indicate a serious condition.